Superworth

Kura Oncology KURA

Drug Manufacturers - General, Healthcare
$9.79
−4.58%
Market cap
$870.9M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
11.3×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$77.2M
Net margin
n/m
outside −100% to 100%
Free cash flow yield
−13.5%

Kura Oncology trades at 11.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $77.2M over the last twelve months.

Charts

Financials

Income statement for KURA, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
n/an/an/an/an/an/a$14.1M$15.3M$20.8M$17.3M$18.3M+30%$20.9M+37%
Cost of revenuen/an/an/an/an/an/an/an/an/an/a$262K$243K
Gross profitn/an/an/an/an/an/an/an/an/an/a$18M$20.6M
R&D$29.3M+17%$32.5M+44%$36.3M+44%$39.7M+41%$41.7M+42%$52.3M+61%$56M+54%$62.8M+58%$67.9M+63%$64.4M+23%$65.3M+17%$61.9M−1%
SG&A$13.1M+13%$14.2M+14%$18.2M+60%$16.7M+41%$18.2M+38%$24.1M+69%$22.8M+26%$25.2M+51%$32.8M+81%$39.1M+63%$31.6M+38%$31.8M+26%
n/an/a−$54.5M−$56.4M−$59.9M−$22.5M−$64.7M+19%−$72.7M+29%−$80M+34%−$86.3M+284%−$78.8M+22%−$73M+1%
Interest expense$404K$394K$398K+9%$406K+5%$412K+2%$403K+2%$382K−4%$391K−4%$393K−5%$346K−14%$336K−12%$345K−12%
Pre-tax incomen/an/a−$49.5M−$50.8M−$54.4M−$17.2M−$57.2M+16%−$66.1M+30%−$74.1M+36%−$80.9M+371%−$73.3M+28%−$68.3M+3%
n/an/an/an/an/an/a$226K$0$0$71K$8K−97%$5K
Net income−$38.6M+9%−$42.8M+29%−$49.5M+45%−$50.8M+37%−$54.4M+41%−$19.2M−55%−$57.4M+16%−$66.1M+30%−$74.1M+36%−$81M+322%−$73.3M+28%−$68.3M+3%
−$0.50−6%−$0.55+12%−$0.59+18%−$0.59+11%−$0.63+26%−$0.22−60%−$0.66+12%−$0.75+27%−$0.85+35%−$0.92+318%−$0.83+26%−$0.77+3%
77.2M+16%77.3M+14%83.9M+23%86.6M+24%87M+13%87.1M+13%87.4M+4%87.6M+1%87.6M+1%88M+1%88.6M+1%88.9M+1%

Gross profit: Q1 FY26 and Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 14 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 14 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Kura Oncology's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
KURAKura Oncology$870.9Mn/mn/a11.3×n/mn/m
ABUSArbutus Biopharma$791.4M5.1×5.6×4.4×n/m84.2%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
AMPHAmphastar Pharmaceuticals$1.1B15.9×20.5×1.6×+1%10.8%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
OMEROmeros$1.3B11.7×11.7×n/mn/mn/m
IRWDIronwood Pharmaceuticals$571.7M4.5×14.8×1.5×+26%33.4%
ANABAnaptysbio$1.4B10.3×99.3×n/mn/mn/m
PBYIPuma Biotechnology$525.5M19.6×12.3×2.3×−3%11.6%
PCRXPacira BioSciences$1.5B104×65.7×1.9×+6%2.0%
ARVNArvinas$491.7M47.0×50.5×1.6×−15%2.9%
Peer median$781.2M13.8×17.0×1.8×+6%11.2%

More on Kura Oncology

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .